2015). Interestingly, combining the DPP‐4 inhibitor vildagliptin with a protein preload contributed to enhance the effect of vildagliptin (Wu et al. 2016). It would be interesting to test whether H80 supplementation can modulate type 2 diabetes and its comorbidities like fatty liver, dyslipidemia, nephropathy or peripheral neuropathy, particularly since GLP‐1 based therapies have shown beneficial effects on these metabolic complications (Przezak, Bielka, and Pawlik 2021; Yaribeygi et al. 2021; Razavi et al. 2022; Mantovani et al. 2021). Here, DPP4 is linked to type 2 diabetes mellitus.